MedTrace Logo

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

NCT02660528 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-10-20

Study results available
· View outcomes & findings →

Summary

This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.

Conditions

Interventions

DRUG

Tocilizumab

Subcutaneous tocilizumab

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Jessica Harder, MD · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660528 on ClinicalTrials.gov